- Home
- CLNN vs MREO Comparison
CLNN vs MREO Comparison
Compare CLNN & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLNN | MREO |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.4M | 50.3M |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CLNN | MREO |
|---|---|---|
| Price | $3.94 | $0.29 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $32.20 | $1.97 |
| AVG Volume (30 Days) | 82.0K | ★ 826.3K |
| Earning Date | 11-12-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | N/A | ★ N/A |
| Revenue | $200,000.00 | ★ $500,000.00 |
| Revenue This Year | $24.70 | N/A |
| Revenue Next Year | $9,228.71 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.02 | $0.20 |
| 52 Week High | $13.50 | $2.37 |
Technical Indicators
Market Signals| Indicator | CLNN | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 50.72 | 42.82 |
| Support Level | $3.13 | $0.27 |
| Resistance Level | $4.05 | $0.35 |
| Average True Range (ATR) | 0.28 | 0.02 |
| MACD | 0.06 | -0.00 |
| Stochastic Oscillator | 82.61 | 25.85 |
Price Performance
Historical ComparisonAbout CLNN Clene Inc.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).